Association of Structural Magnetic Resonance Imaging Measures With Psychosis Onset in Individuals at Clinical High Risk for Developing Psychosis

Maria Jalbrzikowski(University of Pittsburgh), Rebecca A. Hayes(University of Pittsburgh), Stephen J. Wood(Orygen), Dorte Nordholm(Copenhagen University Hospital), Juan Zhou(National University of Singapore), Paolo Fusar‐Poli(University of Pavia), Peter J. Uhlhaas(Charité - Universitätsmedizin Berlin), Tsutomu Takahashi(University of Toyama), Gisela Sugranyes(Centro de Investigación Biomédica en Red de Salud Mental), Yoo Bin Kwak(Seoul National University), Daniel H. Mathalon(San Francisco VA Health Care System), Naoyuki Katagiri(Toho University), Christine I. Hooker(Rush University Medical Center), Lukasz Smigielski(University Hospital of Zurich), Tiziano Colibazzi(Columbia University), Esther Via(Institut de Recerca Sant Joan de Déu), Jinsong Tang(Zhejiang University), Shinsuke Koike(The University of Tokyo), Paul E. Rasser(University of Newcastle Australia), Chantal Michel(University of Bern), И. С. Лебедева(Mental Health Research Center of Russian Academy of Medical Sciences), Wenche ten Velden Hegelstad(Stavanger University Hospital), Camilo de la Fuente‐Sandoval(Instituto Nacional de Neurología y Neurocirugía), James A. Waltz(University of Maryland, Baltimore), Romina Mizrahi(McGill University), Cheryl M. Corcoran(Icahn School of Medicine at Mount Sinai), Franz Resch(University Hospital Heidelberg), Christian K. Tamnes(Diakonhjemmet Hospital), Shalaila S. Haas(Icahn School of Medicine at Mount Sinai), Imke Lemmers-Jansen(Vrije Universiteit Amsterdam), Ingrid Agartz(University of Oslo), Paul Allen(King's College London), G. Paul Amminger(The University of Melbourne), Ole A. Andreassen(University of Oslo), Kimberley Atkinson(University of Edinburgh), Peter Bachman(University of Pittsburgh), Inmaculada Baeza(Universitat de Barcelona), Helen Baldwin(King's College London), Cali F. Bartholomeusz(The University of Melbourne), Stefan Borgwardt(University of Lübeck), Sabrina Catalano(University of Pittsburgh), Michael W.L. Chee(National University of Singapore), Xiaogang Chen(Xiangya Hospital Central South University), Kang Ik K. Cho(Harvard University), Rebecca Cooper(Melbourne Health), Vanessa Cropley(Melbourne Health), Montserrat Dolz(Institut de Recerca Sant Joan de Déu), Bjørn H. Ebdrup(University of Copenhagen), Adriana Fortea(Fundació Clínic per a la Recerca Biomèdica), Louise Birkedal Glenthøj(Copenhagen University Hospital), Birte Glenthøj(University of Copenhagen), Lieuwe de Haan(Arkin), Holly Hamilton(University of California, San Francisco), Mathew A. Harris(University of Edinburgh), Kristen M. Haut(Rush University Medical Center), Ying He(Central South University), Karsten Heekeren(University of Zurich), Andreas Heinz(Charité - Universitätsmedizin Berlin), Daniela Hubl(University of Bern), Wu Jeong Hwang(Seoul National University), Michael Kaess(University of Bern), Kiyoto Kasai(The University of Tokyo), Minah Kim(Seoul National University), Jochen Kindler(University of Bern), Mallory J. Klaunig(University of Maryland, Baltimore County), Alex Koppel(University of Toronto), Tina Dam Kristensen(Copenhagen University Hospital), Jun Soo Kwon(Seoul National University Hospital), Stephen M. Lawrie(University of Edinburgh), Jimmy Lee(Nanyang Technological University), Pablo León-Ortíz(Instituto Nacional de Neurología y Neurocirugía), Ashleigh Lin(The Kids Research Institute Australia), Rachel Loewy(University of California, San Francisco), Xiaoqian Ma(Second Xiangya Hospital of Central South University), Patrick D. McGorry(The University of Melbourne), Philip McGuire(King's College London), Masafumi Mizuno(Toho University), Paul Møller(Vestre Viken Hospital Trust), Tomás Moncada-Habib(Instituto Nacional de Neurología y Neurocirugía), Daniel Muñoz‐Samons(Institut de Recerca Sant Joan de Déu), Barnaby Nelson(The University of Melbourne), Takahiro Nemoto(Toho University), Merete Nordentoft(Copenhagen University Hospital), M. A. Оmelchenkо(Mental Health Research Center of Russian Academy of Medical Sciences), Ketil Oppedal(Stavanger University Hospital), Lijun Ouyang(Central South University), Christos Pantelis(The University of Melbourne), José C. Pariente, Jayachandra M. Raghava(Glostrup Hospital), Francisco Reyes-Madrigal(Instituto Nacional de Neurología y Neurocirugía), Brian J. Roach(University of California, San Francisco), Jan Ivar Røssberg(University of Oslo), Wulf Rössler(Charité - Universitätsmedizin Berlin), Dean F. Salisbury(University of Pittsburgh), Daiki Sasabayashi(University of Toyama), Ulrich Schall(University of Newcastle Australia), Jason Schiffman(University of California, Irvine), Florian Schlagenhauf(Charité - Universitätsmedizin Berlin), André Schmidt(University of Basel), Mikkel Sørensen(Glostrup Hospital), Michio Suzuki(University of Toyama), Anastasia Theodoridou(University Hospital of Zurich), A. S. Tomyshev(Mental Health Research Center of Russian Academy of Medical Sciences), Jordina Tor(Red de Investigación en Actividades Preventivas y Promoción de la Salud), Tor Gunnar Værnes(Oslo University Hospital), Dennis Velakoulis(The Royal Melbourne Hospital), Gloria D. Venegoni(Maastricht University), Sophia Vinogradov(University of Minnesota), Christina Wenneberg(Copenhagen University Hospital), Lars T. Westlye(Oslo University Hospital), Hidenori Yamasue(Hamamatsu University School of Medicine), Yuan Liu(Hunan Institute of Mental Health), Alison R. Yung(Orygen), Thérèse van Amelsvoort(Maastricht University), Jessica A. Turner(Georgia State University), Theo G.M. van Erp(University of California, Irvine), Paul M. Thompson(University of Southern California), Dennis Hernaus(Maastricht University)
JAMA Psychiatry
May 6, 2021
Cited by 135Open Access
Full Text

Abstract

Importance: The ENIGMA clinical high risk (CHR) for psychosis initiative, the largest pooled neuroimaging sample of individuals at CHR to date, aims to discover robust neurobiological markers of psychosis risk. Objective: To investigate baseline structural neuroimaging differences between individuals at CHR and healthy controls as well as between participants at CHR who later developed a psychotic disorder (CHR-PS+) and those who did not (CHR-PS-). Design, Setting, and Participants: In this case-control study, baseline T1-weighted magnetic resonance imaging (MRI) data were pooled from 31 international sites participating in the ENIGMA Clinical High Risk for Psychosis Working Group. CHR status was assessed using the Comprehensive Assessment of At-Risk Mental States or Structured Interview for Prodromal Syndromes. MRI scans were processed using harmonized protocols and analyzed within a mega-analysis and meta-analysis framework from January to October 2020. Main Outcomes and Measures: Measures of regional cortical thickness (CT), surface area, and subcortical volumes were extracted from T1-weighted MRI scans. Independent variables were group (CHR group vs control group) and conversion status (CHR-PS+ group vs CHR-PS- group vs control group). Results: Of the 3169 included participants, 1428 (45.1%) were female, and the mean (SD; range) age was 21.1 (4.9; 9.5-39.9) years. This study included 1792 individuals at CHR and 1377 healthy controls. Using longitudinal clinical information, 253 in the CHR-PS+ group, 1234 in the CHR-PS- group, and 305 at CHR without follow-up data were identified. Compared with healthy controls, individuals at CHR exhibited widespread lower CT measures (mean [range] Cohen d = -0.13 [-0.17 to -0.09]), but not surface area or subcortical volume. Lower CT measures in the fusiform, superior temporal, and paracentral regions were associated with psychosis conversion (mean Cohen d = -0.22; 95% CI, -0.35 to 0.10). Among healthy controls, compared with those in the CHR-PS+ group, age showed a stronger negative association with left fusiform CT measures (F = 9.8; P < .001; q < .001) and left paracentral CT measures (F = 5.9; P = .005; q = .02). Effect sizes representing lower CT associated with psychosis conversion resembled patterns of CT differences observed in ENIGMA studies of schizophrenia (ρ = 0.35; 95% CI, 0.12 to 0.55; P = .004) and individuals with 22q11.2 microdeletion syndrome and a psychotic disorder diagnosis (ρ = 0.43; 95% CI, 0.20 to 0.61; P = .001). Conclusions and Relevance: This study provides evidence for widespread subtle, lower CT measures in individuals at CHR. The pattern of CT measure differences in those in the CHR-PS+ group was similar to those reported in other large-scale investigations of psychosis. Additionally, a subset of these regions displayed abnormal age associations. Widespread disruptions in CT coupled with abnormal age associations in those at CHR may point to disruptions in postnatal brain developmental processes.


Related Papers

No related papers found

Powered by citation graph analysis